Symbols / EXAS
EXAS Chart
About
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 19.74B |
| Enterprise Value | 21.32B | Income | -207.95M | Sales | 3.25B |
| Book/sh | 12.58 | Cash/sh | 5.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7100 | IPO | — |
| P/E | — | Forward P/E | 55.00 | PEG | — |
| P/S | 6.08 | P/B | 8.22 | P/C | — |
| EV/EBITDA | 298.33 | EV/Sales | 6.57 | Quick Ratio | 1.97 |
| Current Ratio | 2.43 | Debt/Eq | 105.57 | LT Debt/Eq | — |
| EPS (ttm) | -1.10 | EPS next Y | 1.88 | EPS Growth | — |
| Revenue Growth | 23.10% | Earnings | 2026-05-07 | ROA | -1.59% |
| ROE | -8.66% | ROIC | — | Gross Margin | 69.69% |
| Oper. Margin | -9.28% | Profit Margin | -6.40% | Shs Outstand | 190.89M |
| Shs Float | 189.12M | Short Float | 3.53% | Short Ratio | 2.85 |
| Short Interest | — | 52W High | 103.54 | 52W Low | 38.81 |
| Beta | 1.42 | Avg Volume | 3.63M | Volume | 231.73K |
| Target Price | $105.81 | Recom | Hold | Prev Close | $103.45 |
| Price | $103.40 | Change | -0.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$105.81
Mean price target
2. Current target
$103.40
Latest analyst target
3. DCF / Fair value
$26.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$103.40
Low
$105.00
High
$118.00
Mean
$105.81
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-20 | down | Mizuho | Outperform → Neutral | $105 |
| 2026-01-05 | down | Evercore ISI Group | Outperform → In-Line | $105 |
| 2025-11-28 | down | Stifel | Buy → Hold | $105 |
| 2025-11-25 | down | Canaccord Genuity | Buy → Hold | $105 |
| 2025-11-24 | down | Benchmark | Buy → Hold | — |
| 2025-11-24 | down | Jefferies | Buy → Hold | $105 |
| 2025-11-21 | down | Wells Fargo | Overweight → Equal-Weight | $105 |
| 2025-11-21 | down | William Blair | Outperform → Market Perform | — |
| 2025-11-21 | down | Guggenheim | Buy → Neutral | — |
| 2025-11-21 | down | Barclays | Overweight → Equal-Weight | $105 |
| 2025-11-20 | down | BTIG | Buy → Neutral | — |
| 2025-11-11 | main | Piper Sandler | Overweight → Overweight | $80 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $85 |
| 2025-11-04 | main | TD Cowen | Buy → Buy | $90 |
| 2025-11-04 | main | Baird | Outperform → Outperform | $88 |
| 2025-11-04 | main | Benchmark | Buy → Buy | $75 |
| 2025-11-04 | main | Guggenheim | Buy → Buy | $75 |
| 2025-11-04 | main | Barclays | Overweight → Overweight | $77 |
| 2025-11-04 | main | Stifel | Buy → Buy | $80 |
| 2025-11-04 | main | BTIG | Buy → Buy | $85 |
- Exact Sciences Stockholders Approve Acquisition by Abbott - Business Wire Fri, 20 Feb 2026 21
- Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up - Zacks Investment Research hu, 19 Feb 2026 12
- CSLLY vs. EXAS: Which Stock Is the Better Value Option? - Yahoo Finance Mon, 16 Feb 2026 08
- Behavioral Patterns of EXAS and Institutional Flows - Stock Traders Daily ue, 24 Feb 2026 15
- Should You Continue to Hold EXAS Stock in Your Portfolio Now? - Nasdaq ue, 30 Dec 2025 08
- Exact Sciences Announces Third Quarter 2025 Results - Stock Titan Mon, 03 Nov 2025 08
- Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance hu, 19 Feb 2026 14
- EXAS Quantitative Stock Analysis - Nasdaq Sat, 13 Dec 2025 08
- Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting - Yahoo Finance Mon, 23 Feb 2026 17
- Why Exact Sciences (EXAS) Stock Is Trading Up Today - Yahoo Finance hu, 04 Sep 2025 07
- Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 10 Nov 2025 08
- Assessing Exact Sciences (EXAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance Wed, 18 Feb 2026 04
- Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 - Yahoo Finance ue, 03 Feb 2026 08
- Exact Sciences (EXAS): Exploring Current Valuation After Recent Share Price Swings - Yahoo Finance Wed, 24 Sep 2025 07
- Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer - Yahoo Finance Fri, 13 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 92523 | — | — | Stock Award(Grant) at price 0.00 per share. | BARANICK BRIAN | Officer | — | 2025-12-24 00:00:00 | D |
| 1 | 42018 | — | — | Stock Award(Grant) at price 0.00 per share. | CONDELLA SARAH K | Officer | — | 2025-12-23 00:00:00 | D |
| 2 | 47208 | nan | — | — | CONDELLA SARAH K | Officer | — | 2025-12-23 00:00:00 | D |
| 3 | 73080 | nan | — | — | BARANICK BRIAN | Officer | — | 2025-12-23 00:00:00 | D |
| 4 | 72320 | — | — | Stock Award(Grant) at price 0.00 per share. | HERRIOTT JAMES | General Counsel | — | 2025-12-23 00:00:00 | D |
| 5 | 33780 | nan | — | — | HERRIOTT JAMES | General Counsel | — | 2025-12-23 00:00:00 | D |
| 6 | 63099 | nan | — | — | BLOOMER AARON | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 7 | 72523 | — | — | Stock Award(Grant) at price 0.00 per share. | ORVILLE JACOB A | Officer | — | 2025-12-23 00:00:00 | D |
| 8 | 73080 | nan | — | — | ORVILLE JACOB A | Officer | — | 2025-12-23 00:00:00 | D |
| 9 | 713931 | — | — | Stock Award(Grant) at price 0.00 per share. | CONROY KEVIN T | Chief Executive Officer | — | 2025-12-23 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 7.26M | -5.78M | 8.91M | -460.12K |
| TaxRateForCalcs | 0.21 | 0.01 | 0.21 | 0.01 |
| NormalizedEBITDA | 17.87M | 30.32M | -13.13M | -385.71M |
| TotalUnusualItems | 34.57M | -819.65M | 42.42M | -35.39M |
| TotalUnusualItemsExcludingGoodwill | 34.57M | -819.65M | 42.42M | -35.39M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -207.95M | -1.03B | -204.15M | -623.51M |
| ReconciledDepreciation | 221.58M | 214.86M | 206.61M | 197.56M |
| ReconciledCostOfRevenue | 984.24M | 840.15M | 737.56M | 661.36M |
| EBITDA | 52.44M | -789.33M | 29.28M | -421.11M |
| EBIT | -169.14M | -1.00B | -177.32M | -618.66M |
| NetInterestIncome | -39.36M | -37.27M | -29.77M | -19.63M |
| InterestExpense | 34.75M | 31.97M | 24.42M | 13.91M |
| NormalizedIncome | -235.26M | -214.99M | -237.66M | -588.57M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -207.95M | -1.03B | -204.15M | -623.51M |
| TotalExpenses | 3.45B | 2.94B | 2.71B | 2.66B |
| TotalOperatingIncomeAsReported | -206.30M | -1.05B | -215.01M | -593.51M |
| DilutedAverageShares | 188.69M | 184.20M | 180.14M | 176.35M |
| BasicAverageShares | 188.69M | 184.20M | 180.14M | 176.35M |
| DilutedEPS | -1.10 | -5.59 | -1.13 | -3.54 |
| BasicEPS | -1.10 | -5.59 | -1.13 | -3.54 |
| DilutedNIAvailtoComStockholders | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncomeCommonStockholders | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncome | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncomeIncludingNoncontrollingInterests | -207.95M | -1.03B | -204.15M | -623.51M |
| NetIncomeContinuousOperations | -207.95M | -1.03B | -204.15M | -623.51M |
| TaxProvision | 4.06M | -7.30M | 2.40M | -9.06M |
| PretaxIncome | -203.89M | -1.04B | -201.75M | -632.57M |
| OtherIncomeExpense | 34.57M | -819.65M | 42.42M | -35.39M |
| SpecialIncomeCharges | -7.20M | -859.21M | 9.70M | -15.97M |
| OtherSpecialCharges | -10.25M | -10.32M | ||
| ImpairmentOfCapitalAssets | 7.20M | 869.46M | 621.00K | 15.97M |
| GainOnSaleOfSecurity | 41.77M | 39.56M | 32.71M | -19.43M |
| NetNonOperatingInterestIncomeExpense | -39.36M | -37.27M | -29.77M | -19.63M |
| TotalOtherFinanceCost | 4.61M | 5.30M | 5.35M | 5.73M |
| InterestExpenseNonOperating | 34.75M | 31.97M | 24.42M | 13.91M |
| OperatingIncome | -199.10M | -179.24M | -214.39M | -577.54M |
| OperatingExpense | 2.46B | 2.10B | 1.98B | 2.00B |
| OtherOperatingExpenses | -9.20M | -78.43M | 13.24M | |
| DepreciationAmortizationDepletionIncomeStatement | 7.70M | 92.16M | 97.45M | 95.00M |
| DepreciationAndAmortizationInIncomeStatement | 7.70M | 92.16M | 97.45M | 95.00M |
| Amortization | 7.70M | 92.16M | 97.45M | 95.00M |
| AmortizationOfIntangiblesIncomeStatement | 7.70M | 92.16M | 97.45M | 95.00M |
| ResearchAndDevelopment | 523.00M | 431.21M | 426.93M | 394.19M |
| SellingGeneralAndAdministration | 1.94B | 1.68B | 1.63B | 1.59B |
| SellingAndMarketingExpense | 1.05B | 894.12M | 827.80M | 929.64M |
| GeneralAndAdministrativeExpense | 888.67M | 781.83M | 800.29M | 663.38M |
| OtherGandA | 888.67M | 781.83M | 800.29M | 663.38M |
| SalariesAndWages | 1.00B | 977.80M | 989.50M | 533.10M |
| GrossProfit | 2.26B | 1.92B | 1.76B | 1.42B |
| CostOfRevenue | 984.24M | 840.15M | 737.56M | 661.36M |
| TotalRevenue | 3.25B | 2.76B | 2.50B | 2.08B |
| OperatingRevenue | 3.25B | 2.76B | 2.50B | 2.08B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 189.92M | 185.62M | 181.36M | 177.93M |
| ShareIssued | 189.92M | 185.62M | 181.36M | 177.93M |
| NetDebt | 1.37B | 1.97B | 1.76B | 1.99B |
| TotalDebt | 2.52B | 2.75B | 2.55B | 2.45B |
| TangibleBookValue | -886.92M | -974.12M | -1.11B | -1.26B |
| InvestedCapital | 4.73B | 4.97B | 5.51B | 5.28B |
| WorkingCapital | 914.70M | 839.24M | 679.67M | 569.51M |
| NetTangibleAssets | -886.92M | -974.12M | -1.11B | -1.26B |
| CapitalLeaseObligations | 195.52M | 184.54M | 190.45M | 210.76M |
| CommonStockEquity | 2.40B | 2.40B | 3.15B | 3.04B |
| TotalCapitalization | 4.73B | 4.72B | 5.46B | 5.28B |
| TotalEquityGrossMinorityInterest | 2.40B | 2.40B | 3.15B | 3.04B |
| StockholdersEquity | 2.40B | 2.40B | 3.15B | 3.04B |
| GainsLossesNotAffectingRetainedEarnings | 2.36M | -944.00K | 1.43M | -5.24M |
| OtherEquityAdjustments | 2.36M | -944.00K | 1.43M | -5.24M |
| RetainedEarnings | -4.71B | -4.50B | -3.47B | -3.27B |
| AdditionalPaidInCapital | 7.10B | 6.90B | 6.61B | 6.31B |
| CapitalStock | 1.91M | 1.86M | 1.81M | 1.78M |
| CommonStock | 1.91M | 1.86M | 1.81M | 1.78M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.46B | 3.53B | 3.33B | 3.18B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.82B | 2.79B | 2.81B | 2.77B |
| OtherNonCurrentLiabilities | 329.32M | 315.50M | 335.98M | 352.46M |
| LongTermDebtAndCapitalLeaseObligation | 2.49B | 2.48B | 2.48B | 2.42B |
| LongTermCapitalLeaseObligation | 161.93M | 157.13M | 161.07M | 182.40M |
| LongTermDebt | 2.33B | 2.32B | 2.31B | 2.24B |
| CurrentLiabilities | 641.15M | 732.19M | 514.70M | 412.75M |
| OtherCurrentLiabilities | 15.22M | 37.77M | 14.82M | 10.25M |
| CurrentDebtAndCapitalLeaseObligation | 33.59M | 276.56M | 79.38M | 28.37M |
| CurrentCapitalLeaseObligation | 33.59M | 27.41M | 29.38M | 28.37M |
| CurrentDebt | 249.15M | 50.00M | ||
| OtherCurrentBorrowings | 249.15M | 50.00M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 276.66M | 185.93M | 247.62M | 201.25M |
| PayablesAndAccruedExpenses | 315.68M | 231.93M | 172.88M | 172.88M |
| CurrentAccruedExpenses | 139.81M | 142.36M | 94.06M | 97.96M |
| Payables | 175.87M | 89.57M | 78.82M | 74.92M |
| AccountsPayable | 175.87M | 89.57M | 78.82M | 74.92M |
| TotalAssets | 5.86B | 5.93B | 6.47B | 6.23B |
| TotalNonCurrentAssets | 4.30B | 4.36B | 5.28B | 5.24B |
| OtherNonCurrentAssets | 185.81M | 169.72M | 177.39M | 90.58M |
| GoodwillAndOtherIntangibleAssets | 3.29B | 3.38B | 4.26B | 4.30B |
| OtherIntangibleAssets | 919.92M | 1.01B | 1.89B | 1.96B |
| Goodwill | 2.37B | 2.37B | 2.37B | 2.35B |
| NetPPE | 831.00M | 810.62M | 842.06M | 851.76M |
| AccumulatedDepreciation | -604.13M | -508.57M | -417.20M | -307.59M |
| GrossPPE | 1.44B | 1.32B | 1.26B | 1.16B |
| Leases | 257.50M | 227.88M | 214.56M | 200.59M |
| ConstructionInProgress | 84.14M | 89.06M | 104.59M | 68.40M |
| OtherProperties | 122.33M | 116.95M | 143.71M | 167.00M |
| MachineryFurnitureEquipment | 668.91M | 583.06M | 494.18M | 423.29M |
| BuildingsAndImprovements | 290.78M | 290.78M | 290.78M | 288.94M |
| LandAndImprovements | 11.46M | 11.46M | 11.45M | 11.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.56B | 1.57B | 1.19B | 982.26M |
| OtherCurrentAssets | 126.28M | 122.05M | 85.63M | 73.90M |
| PrepaidAssets | 74.12M | |||
| Inventory | 166.20M | 162.38M | 127.47M | 118.26M |
| FinishedGoods | 57.05M | 53.67M | ||
| WorkInProcess | 90.48M | 92.65M | 68.88M | 57.05M |
| RawMaterials | 75.72M | 69.73M | 58.59M | 61.21M |
| Receivables | 298.65M | 248.97M | 203.62M | 158.04M |
| AccountsReceivable | 298.65M | 248.97M | 203.62M | 158.04M |
| CashCashEquivalentsAndShortTermInvestments | 964.71M | 1.04B | 777.64M | 632.06M |
| OtherShortTermInvestments | 8.71M | 437.14M | 172.27M | 389.56M |
| CashAndCashEquivalents | 956.00M | 600.89M | 605.38M | 242.49M |
| CashEquivalents | 0.00 | 5.34M | 75.28M | 64.33M |
| CashFinancial | 956.00M | 595.55M | 530.10M | 178.17M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 356.78M | 74.55M | 31.93M | -438.02M |
| RepaymentOfDebt | -249.17M | -50.00M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 266.75M | 137.98M | 50.00M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -134.66M | -135.99M | -124.19M | -214.46M |
| InterestPaidSupplementalData | 30.44M | 27.84M | 18.78M | 11.52M |
| EndCashPosition | 956.00M | 606.64M | 609.67M | 242.79M |
| BeginningCashPosition | 606.64M | 609.67M | 242.79M | 315.77M |
| EffectOfExchangeRateChanges | 891.00K | -3.29M | 1.32M | 30.00K |
| ChangesInCash | 348.47M | 255.00K | 365.56M | -73.01M |
| FinancingCashFlow | -338.09M | 231.87M | 159.77M | 76.48M |
| CashFlowFromContinuingFinancingActivities | -338.09M | 231.87M | 159.77M | 76.48M |
| NetOtherFinancingCharges | -117.36M | -17.75M | -9.75M | -5.53M |
| ProceedsFromStockOptionExercised | 28.45M | 32.88M | 31.54M | 32.02M |
| NetCommonStockIssuance | 0.00 | 0.00 | ||
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | -249.17M | 216.75M | 137.98M | 50.00M |
| NetLongTermDebtIssuance | -249.17M | 216.75M | 137.98M | 50.00M |
| LongTermDebtPayments | -249.17M | -50.00M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 266.75M | 137.98M | 50.00M |
| InvestingCashFlow | 195.12M | -442.15M | 49.68M | 74.07M |
| CashFlowFromContinuingInvestingActivities | 195.12M | -442.15M | 49.68M | 74.07M |
| NetOtherInvestingChanges | -46.73M | -45.23M | -250.00K | 24.45M |
| NetInvestmentPurchaseAndSale | 376.51M | -260.94M | 226.53M | 278.76M |
| SaleOfInvestment | 572.28M | 205.82M | 382.95M | 453.07M |
| PurchaseOfInvestment | -195.77M | -466.76M | -156.42M | -174.31M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -52.41M | -14.69M |
| PurchaseOfBusiness | 0.00 | 0.00 | -52.41M | -14.69M |
| NetPPEPurchaseAndSale | -134.66M | -135.99M | -124.19M | -214.46M |
| PurchaseOfPPE | -134.66M | -135.99M | -124.19M | -214.46M |
| OperatingCashFlow | 491.44M | 210.54M | 156.12M | -223.56M |
| CashFlowFromContinuingOperatingActivities | 491.44M | 210.54M | 156.12M | -223.56M |
| ChangeInWorkingCapital | 121.83M | -56.01M | -342.00K | -26.38M |
| ChangeInOtherWorkingCapital | -1.41M | -57.94M | ||
| ChangeInOtherCurrentLiabilities | -33.76M | -16.06M | -20.37M | -21.97M |
| ChangeInOtherCurrentAssets | -5.79M | -2.32M | -11.62M | -84.00K |
| ChangeInPayablesAndAccruedExpense | 214.04M | 43.54M | 82.75M | -52.18M |
| ChangeInInventory | -3.77M | -34.91M | -7.69M | -13.23M |
| ChangeInReceivables | -48.89M | -46.26M | -43.42M | 61.09M |
| ChangesInAccountReceivables | -48.89M | -46.26M | -43.42M | 61.09M |
| OtherNonCashItems | 135.74M | 13.86M | -62.55M | -17.14M |
| StockBasedCompensation | 217.67M | 214.88M | 231.31M | 206.82M |
| UnrealizedGainLossOnInvestmentSecurities | 11.77M | 1.49M | ||
| AssetImpairmentCharge | 7.20M | 869.46M | 621.00K | 15.97M |
| AmortizationOfSecurities | 1.84M | 4.62M | ||
| DeferredTax | -1.54M | -10.12M | -955.00K | -11.90M |
| DeferredIncomeTax | -1.54M | -10.12M | -955.00K | -11.90M |
| DepreciationAmortizationDepletion | 221.58M | 214.86M | 206.61M | 197.56M |
| DepreciationAndAmortization | 221.58M | 214.86M | 206.61M | 197.56M |
| AmortizationCashFlow | 96.70M | 95.16M | 92.16M | 97.45M |
| AmortizationOfIntangibles | 96.70M | 95.16M | 92.16M | 97.45M |
| Depreciation | 124.88M | 119.70M | 114.45M | 100.11M |
| OperatingGainsLosses | -3.08M | -7.54M | -14.42M | 35.02M |
| GainLossOnInvestmentSecurities | -3.08M | 2.71M | -4.10M | 21.77M |
| GainLossOnSaleOfPPE | 1.86M | 1.05M | ||
| NetIncomeFromContinuingOperations | -207.95M | -1.03B | -204.15M | -623.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EXAS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|